Empowering Nordic healthtech change how the world cares

Tidewave R&D

Tidewave R&D develops assistive aids for people with reduced mobility to increase the quality of life for patients and create safer work environments for caregivers. The Tidewave turning mattress ​prevents and treats pressure ulcers up to and incl. grade 4. Usually caregivers perform manual turning on patients, which is painful and sleep disturbing. The Tidewave mattress provides continuous turning up to a 30 degrees angle and more safety through the unique curved shape around the body.

Boneprox

Osteoporosis is one of the biggest cost drivers in healthcare. Today, the disease is often detected after a fracture occurs, but through an early detection, the disease can be prevented with simple lifestyle changes. Boneprox is a patented software with artificial intelligence (AI) that detects osteoporosis through dental x-rays, and thereby finds risk patients before the first fracture occurs.

Joint Academy

Joint Academy connects patients with licensed physical therapists to deliver online treatments for chronic joint and back pain.

Cross Technology Solutions

Cross Technology Solutions is a Swedish medtech innovation company that develops the eHealth platform LifePod for remote monitoring of patients with chronic conditions or other needs that should be continuously followed.

LifePod identifies and automatically grades chronical patients’ medical priority using smart algorithms. LifePod is used in hospitals and primary care centers within a dozen different diagnostic areas, including cardiovascular diseases, kidney diseases, post-surgical follow-up.

cross-solutions.com

Product on the market

Key Benefits

• LifePod frees up working hours for healthcare professionals and makes it possible to take care of 20-40% more patients
• LifePod creates significant saving opportunities – socio-economic savings of 22 percent if you use LifePod instead of traditional care for patients with cardiovascular disease
• 20% reduced risk to suffer a cardiovascular event like infarction or stroke
• Better risk factor management, adherence to medical advices and increased quality of life
• LifePod is a CE-approved medical device product in CE class IIa and developed in Sweden

Recent News

• lifesciencesweden.se/article/view/818472/vdbyte_pa_cross_ska_starka_marknadssidan
• cross-solutions.com/new-market-oriented-ceo-to-cross
• it-halsa.se/category/partnerzone/cross-technology-solutions

Sweden, Adherence, Cancer, Cardiovascular diseases, Chronic conditions/disabilities, Data efficiency, Respiratory diseases, Unhealthy lifestyle, Adults, Care professionals, Elderly, People in general, Elderly care providers, Hospital care providers, Insurance companies, Pharmacy/pharma, Pre-hospital emergency care providers, Primary care providers, Specialist care providers

Qinematic

Musculoskeletal problems affect 1 in 2 people, with 100M people in the EU with chronic pain and 40% without a diagnosis.
Qinematic is a movement intelligence company that develops and licenses Moovment(R) software to help people move well so they can move more. It is used by health professionals to quickly record and analyse human movement in 3D, and by consumers to track their progress using 2D video from a mobile phone. Corrective exercises and results are shared in a web application.

moovment.pro

Product on the market

Key Benefits

• 6 min 3D digital assessment vs 90 min 3D lab test
• 40 scans per day vs 8 assessments per day by a health professional
• Remote exercise prescription in 5 minutes
• 10% of the cost of a 3D lab test
• Single camera system with CAPEX of €2500 vs €80-200,000 for multicamera system

Recent News

• di.se/nyheter/nya-premiemodellen-lev-halsosamt-fa-billigare-forsakring
• hannover-re.com/1809727/qinematic startup.info/glenn-bilby-qinematic
• dailynews.lk/2020/01/13/tc/208122/first-sri-lanka-offer-advanced-scanning-software-sweden

Sweden, Osteoarthritis, Unhealthy lifestyle, Care professionals, People in general, Patients/consumers, Insurance companies, Other industry, Primary care providers, Specialist care providers

Oppioo

1/3 will at some point get cancer (globally 18M people every year), a disease associated with suffering and long recovery. The numbers of cancer patients are growing, but the survival rate increases, which means we have an increasing number of cancer survivors with life-long side effects from their treatment. Oppioo integrates individualized cancer rehabilitation in an early stage, to reduce side effects, complications, risk of relapse as well as speed up recovery and increase well-being.

oppioo.com

Product in development

Key Benefits

• Increase well-being.
• Lower cost of sick leave.
• Patient empowerment.
• Contribute to precision health.

Recent News

• linkedin.com/company/oppioo

Sweden, Admin workload, Cancer, Chronic conditions/disabilities, Data efficiency, Patient-profession communication, Adolescents, Adults, Care professionals, Researchers, Patients/consumers, Hospital care providers, Insurance companies, Pharmacy/pharma, Primary care providers, Specialist care providers

Remente

Remente is a mental wellbeing app for personal and organizational growth. Using our psychology based tools, Remente improves mental wellbeing, productivity and motivation thus helping individuals build mental resilience, improve productivity and maintain motivation.

OnDosis

Revolutionizing how patients take their medicine. Everyone deserves to live a good life, but for many that’s only possible with just the right medication. We want to help here by starting a revolution combining traditional pharmaceuticals, individualized dosing and digital health solutions.

Digital Diabetes Analytics

Digital Diabetes Analytics is on a mission to revolutionize diabetes care with powerful digital tools based on big data and machine learning. We aim to improve the quality of life for both type 1 and 2 diabetes patients. Our product is a Software as a Service (SaaS) for patients and healthcare providers enabling remote monitoring and visits with automatic and remote glucose data monitoring.